Safeguard Scientifics Q1 net loss $6.7M; strategic review with Houlihan Lokey continues

SAFEGUARD SCIENTIFICS INC

2022-Q1 EPS reported -$0.40

Net loss $6.7M ($0.40 per share) vs net income $17.6M ($0.84 per share) in Q1 2021.
Repurchased 147,795 shares at avg $5.27 in Q1; additional $0.4M post-quarter at $4.71.
Funded $2.0M convertible loan to Prognos Health and $1.4M to Clutch Holdings.
Carrying value of ownership interests $24.1M vs cost $154.4M; Bright Health fair value $2.6M.
Strategic review with Houlihan Lokey ongoing; update expected by Q3 2022 earnings call.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.